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Abstract
Background: In the United Kingdom, patients with locally advanced rectal cancer
routinely receive neoadjuvant chemoradiotherapy. However, the effects of this on
physical fitness are unclear. This pilot study is aimed to investigate the effect of
neoadjuvant chemoradiotherapy on objectively measured in vivo muscle
mitochondrial function and whole-body physical fitness.
Methods: We prospectively studied 12 patients with rectal cancer who completed
standardized neoadjuvant chemoradiotherapy, recruited from a large tertiary cancer
centre, between October 2012 and July 2013. All patients underwent a
cardiopulmonary exercise test and a phosphorus magnetic resonance
spectroscopy quadriceps muscle exercise-recovery study before and after
neoadjuvant chemoradiotherapy. Data were analysed and reported blind to patient
identity and clinical course. Primary variables of interest were the two physical
fitness measures; oxygen uptake at estimated anaerobic threshold and oxygen
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uptake at Peak exercise (ml.kg21.min21), and the post-exercise phosphocreatine
recovery rate constant (min21), a measure of muscle mitochondrial capacity in vivo.
Results: Median age was 67 years (IQR 64–75). Differences (95%CI) in all three
primary variables were significantly negative post-NACRT: Oxygen uptake at
estimated anaerobic threshold 22.4 ml.kg21.min21 (23.8, 20.9), p50.004;
Oxygen uptake at Peak 24.0 ml.kg21.min21 (26.8, 21.1), p50.011; and post-
exercise phosphocreatine recovery rate constant 20.34 min21 (20.51, 20.17),
p,0.001.
Conclusion: The significant decrease in both whole-body physical fitness and in
vivo muscle mitochondrial function raises the possibility that muscle mitochondrial
mechanisms, no doubt multifactorial, may be important in deterioration of physical
fitness following neoadjuvant chemoradiotherapy. This may have implications for
targeted interventions to improve physical fitness pre-surgery.
Trial Registration: Clinicaltrials.gov registration NCT01859442
Introduction
In the UK colorectal cancer is the third commonest cause of cancer death [1, 2]. In
2013, ,9000 patients were diagnosed with rectal cancer (35% aged .75 y), of
whom ,4600 underwent major resection with a 90-day elective postoperative
mortality of 2.5% [3]. 25% are locally advanced (Tumour, Node, Metastasis
(TNM) stage - T3/T4N+) cancers (i.e. resection margin threatened) considered
for neoadjuvant chemoradiotherapy (NACRT) to control local disease and to
achieve tumour downsizing and negative resection margins [4–8]; however,
external beam radiation and oral or intravenous fluoropyrimidines causes dose-
limiting toxicity, reaching Grade 3–5 in 20% (Common Terminology Criteria for
Adverse Events, Version 3.0). It is unknown to what extent NACRT affects
physical fitness in this patient cohort.
Poor physical fitness, assessed by cardiopulmonary exercise testing (CPET), is
linked to poor postoperative outcomes after major surgery [9–15]. CPET provides
an integrated quantitative assessment of the cardiorespiratory system at rest and
under the stress of maximal exercise, testing the physiological reserve required to
withstand the stress of surgery. Subjective assessment tools have been used to
predict surgical outcomes, but there is little evidence linking objectively-measured
physical fitness and surgical outcome in this group. The UK National Bowel
Cancer Audit found the American Society of Anaesthesiologists – Physical Status
(ASA-PS) score (a categorical descriptor of fitness for surgery) to be the strongest
predictor of death within 30 days of surgery [16]. Only two trials have suggested
that rectal cancer patients with a higher subjective performance status (WHO
Score .1) have worse post-operative outcome after combined chemotherapy or
chemo-radiation and surgery [17, 18]. Studies investigating objective changes in
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Medical, Deltex Medical, London Clinic, Rolex.),
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physical fitness in patients receiving neoadjuvant cancer treatments are lacking
[19]. We have previously demonstrated a significant reduction in objectively
measured physical fitness with neoadjuvant chemotherapy in upper gastro-
intestinal cancer which was associated with reduced 1 year survival [20] and a
similar reduction in fitness with neoadjuvant chemoradiotherapy in rectal cancer
which was associated with in-hospital morbidity [21]. Whether and how this
impaired physical fitness relates to changes in mitochondrial function is
unknown.
Skeletal muscle mitochondrial function can be studied non-invasively in vivo
using phosphorus magnetic resonance spectroscopy (31P MRS) [22]; this can
usefully be combined with CPET measurements [23, 24] of whole-body fitness, to
which muscle mitochondrial function makes a substantial contribution. Good
correlations are observed between in vivo and in vitro measures of mitochondrial
function in health and chronic conditions (e.g. type 2 diabetes) makes the
assessment of mitochondrial function by 31P MRS an attractive and reliable
modality, especially for repeated measurements [24–26].
The primary aim of this pilot study was to evaluate changes in objectively-
measured physical fitness and skeletal muscle mitochondrial function after
standardized NACRT, in patients scheduled for rectal cancer surgery. An
exploratory aim was to observe changes in physical activity (PA) in the same
patient cohort.
Methods
Patients and clinical methods
The protocol for this trial and supporting TREND checklist are available as
supporting information; see Checklist S1 and Protocol S1. This nested
mechanism pilot study forms part of a larger clinical trial which began in March
2011. Ethics approval for the main trial was given by the North West – Liverpool
East Research and Ethics Committee (11/H1002/12) in March 2011, with a
subsequent amendment (11/H1002/12c) adding 31P MRS measurements for this
nested mechanism pilot sub-study approved in January 2012. The larger trial was
registered with clinicaltrials.gov (NCT01325909 – March 2011), and initially this
NCT registration was taken to cover all aspects of the larger trial, including the
present pilot study. Subsequently the pilot study was registered separately (NCT
01859442 – May 2013), and as a result of this change of approach this specific
registration post-dated the recruitment of the first patients reported here, for
which studies commenced in October 2012. The authors confirm that all ongoing
and related trials for this intervention are registered. Written informed consent
was obtained from all patients. All patients were followed up until surgery, with
the last patient exiting the study in October 2013.
We recruited consecutive patients between October 2012 and July 2013 who
were referred to the Colorectal Multi-Disciplinary Team (MDT), age >18 y, with
locally advanced resectable rectal cancer (circumferential resection margin
Mitochondrial Function after Cancer Therapy
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threatened), scheduled for standardized NACRT on the basis of Tumour, Node,
Metastasis (TNM) classification .T2/N+ with no distant metastasis [27] and
WHO Performance Status ,2 [28]. Predefined exclusion criteria were: inability to
give informed consent, non-resectable disease, standard MR exclusion criteria,
inability to exercise studies due to leg dysfunction, and patients who declined
surgery or NACRT, or who received non-standard NACRT.
TNM staging involved flexible sigmoidoscopy for histological diagnosis,
colonoscopy, chest, abdomen and pelvis computer-aided tomography (CT) and a
1.5T pelvic magnetic resonance imaging (MRI). All patients then underwent
standardised NACRT for 5 weeks. Standardized radiotherapy consisted of 45 Gy
in 25 fractions on weekdays using a 3-dimensional conformal technique with CT
guidance. A boost dose was given (5.4 Gy in 3 fractions) to the primary tumour
only. Oral capecitabine (825 mg.m22) was given twice daily on radiotherapy days.
No patients received brachytherapy. The colorectal multidisciplinary team (MDT)
was blind to CPET results, which therefore did not influence perioperative
management. All patients underwent total mesorectal excision (TME) surgery
[29]. A defunctioning stoma was constructed at the discretion of the surgeon. No
deviations from the protocol were encountered.
CPET
CPET (Geratherm Respiratory GmbH; Love Medical Ltd, Manchester, United
Kingdom) and the estimation of the estimated anaerobic threshold followed a
standard protocol described in detail elsewhere [14]. Patient characteristics
recorded included age, gender, height, weight, diagnosis, staging, surgical
procedure planned, WHO classification, ASA-PS, and diagnoses of diabetes,
ischaemic heart disease, cerebrovascular disease, or heart failure. Resting flow-
volume loops were used to derive Forced Expiratory Volume over 1 second
(FEV1) and Forced Vital Capacity (FVC). Ventilation and gas exchange variables
included oxygen uptake ( _Vo2), ventilatory equivalents for oxygen and carbon
dioxide ( _VE/ _Vo2; _VE/ _Vco2) and oxygen pulse ( _Vo2/heart rate), all measured both
at estimated anaerobic threshold (h^L) and at peak exercise.
NACRT associated toxicity and CPET-related adverse events were discussed at
the weekly MDT meeting. Toxicity events were graded on the National Cancer
Institute Common Terminology Criteria (version 3.0), and acute radiation-
induced skin toxicity using the Radiation Therapy Oncology Group scoring
system.
Physical activity
PA was measured during a continuous 72 h period using a biaxial accelerometer
(SenseWear armband BodyMedia Inc., Pittsburgh, USA), worn over the right
triceps during weekdays at baseline and post-NACRT. Step count while active
averaged over the whole 72 h was used as a measure of PA. All patients were
Mitochondrial Function after Cancer Therapy
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instructed not to change their PA, and to continue performing normal activities of
daily living throughout the study period.
MRS methods
31P MRS assessments of muscle mitochondrial function in quadriceps were
carried out using a Siemens 3T Trio MR scanner (Siemens AG, Erlangen,
Germany) using an isometric knee extension exercise protocol. Subjects lay supine
(secured with a Velcro strap across the hips) with the right knee flexed over a rigid
foam support in a custom-built rig permitting isometric knee extension exercise
against a strap across the anterior lower shin/ankle connected to an aluminium
bar fitted with a strain gauge. 31P MRS data were acquired from right quadriceps
muscle using a dual-tuned 18 cm/15 cm diameter 31P/1H surface coil (RAPID
Biomedical, Rimpar, Germany), Velcro-strapped to the anterior thigh (midway
between anterior superior iliac spine and patella). After automated set-up and
manual shimming using tissue water signal, a 4-scan fully relaxed (TR510s)
spectrum and a 32-scan partially saturated (TR52s) resting spectrum were
collected. The exercise protocol consisted of 5 min rest followed by 2 bouts of
isometric exercise (paced at 2 s on, 2 s off by an audible cue, exercise force being
fed back visually via an LED display) each followed by 7 min recovery, while
spectra were collected (TR52s) every 8 s. Two exercise intensities were used,
corresponding to 70% and 90% of maximal voluntary contraction established in 3
brief trials prior to MRS acquisition (in pilot experiments these intensities gave
acceptable PCr depletion with minimal acidification in typical subjects). Block
MRS data output files from exercise-recovery acquisitions were converted to text
using a specially-written MATLAB routine. All 31P MRS data were processed using
the java-based Magnetic Resonance User Interface (jMRUI v.3.0), using the
AMARES time-domain fitting algorithm. Data were fitted assuming Lorentzian
lineshapes for phosphocreatine (PCr), inorganic phosphate (Pi) and ATP (b-ATP
a 1:2:1 triplet, a-ATP and c-ATP both 1:1 doublets). The chemical shift of Pi
relative to PCr was used by standard means to determine intracellular pH. PCr
recovery time courses were fitted to a monoexponential function to estimate the
recovery rate constant (kPCr min
21): in the absence of appreciable changes in pH,
this is an accepted measure of effective muscle mitochondrial function. As kPCr
did not differ significantly between the two exercise intensities, and as pH changes
were small throughout, values of kPCr are presented as mean of the two intensities
[30].
All patients underwent CPET, PA monitoring and 31P MRS 2 weeks before
NACRT (baseline) and immediately post-NACRT (post-NACRT) that is within
48 hours of finishing NACRT. CPET data were reported by two experienced
assessors blind to patient demographics and data time-points. Any CPET or
exercise-related adverse events were discussed at the weekly colorectal MDT
meeting. 31P MRS analysis was performed blind to clinical details and CPET data.
Our primary outcome variables include _Vo2 at h^L, _Vo2 Peak and kPCr, assessed
with CPET and 31P MRS; an exploratory outcome variable is the number of steps
Mitochondrial Function after Cancer Therapy
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whilst active, assessed by PA monitoring. A comparison of these variables is made
between baseline and post-NACRT.
Statistical methods
Our aim was to recruit 12 patients to a pilot study who would undergo
standardised NACRT, CPET and 31P MRS scans at baseline (pre-NACRT) and
immediately post-NACRT. No formal sample size calculation was performed as
this study was designed as a nested pilot study: the target number was based on
experience and reports of similar clinical 31P MRS studies and pragmatic
considerations of recruitment logistics and funding. Descriptive statistics are
reported as mean (SD) or median and inter-quartile range (IQR) depending on
the distribution and categorical statistics as frequency (percentage). Normality
was assessed by the Shapiro-Wilk test. Pre- and post-NACRT data were compared
using paired t-tests.
For the primary analysis, baseline and post-NACRT measurements for _Vo2 at
h^L, _Vo2 Peak and kPCr were compared using a paired t-test as an intention to treat.
Formal comparisons were considered to be statistically significant at p,0.05.
Spearman’s correlation coefficient (r) was used to describe the strength of
association between changes in _Vo2 at h^L and change in haemoglobin. For PA
these comparisons were considered as exploratory and tested against the
uncorrected 5% significance level; the need to square-root transform PA makes it
impossible to recover the differences and confidence intervals on a meaningful
scale, so only p-values and predicted means are presented. These analyses were
conducted using Stata version 12 (StataCorp. 2011. Stata Statistical Software:
Release 12. College Station, TX: StataCorp LP.)
Results
Patient flow and characteristics
Fifteen patients were eligible for surgery, of which 3 were recruited into a different
trial; 12 patients (10 males and 2 females) were recruited and underwent CPET
and 31P MRS prior to starting a standardised course of NACRT (Figure 1). All
CPETs were carried out 48¡5 hours before the 31P MRS scan both at baseline
and post-NACRT. All patients underwent CPET and 31P MRS immediately after
(post-NACRT) finishing NACRT (at a maximum of 48¡5 hours). Table 1
describes baseline patient characteristics and Table 2 describes patient character-
istics between baseline and post-NACRT. There were no significant changes in
BMI or lung function following NACRT, but there was a small but significant fall
in haemoglobin. 83% of diagnosed rectal cancers were T3 with threatened
circumferential resection margins.
Mitochondrial Function after Cancer Therapy
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Chemoradiotherapy and acute toxicity
The mean cumulative dose of capecitabine was 96% (range 84–100%) of the
planned treatment dose; 1 patient needed dose reduction. All but 1 patient
received at least 45 Gy radiotherapy, and all completed the full 25 fractions. 2
patients (including 1 receiving a diverting stoma because of obstructive symptoms
prior to NACRT) experienced grade 3 toxicity, notably diarrhoea and radiation
dermatitis, but no grade 4 toxicity was reported.
The effect of NACRT on physical fitness, physical activity and
mitochondrial function
Table 3 shows CPET, PA and 31P MRS-derived variables pre- and post-NACRT.
No exercise or MRS adverse events were encountered until end of follow-up. Post-
NACRT, there were significant decreases in both absolute (ml.min21) and relative
(ml.kg21.min21) _Vo2, in O2 pulse at h^L and at Peak exercise, in baseline heart rate,
in kPCr and in the number of steps (although this is strongly influenced by an
apparent outlier; difference in the number of steps was not significant after the
outlier was removed); Figure 2 shows mean and individual values of kPCr, _Vo2 at
h^L and _Vo2 at Peak, while Figure 3 shows the mean number of daily steps. _VE/
_Vco2 and work rates at h^L and Peak exercise did not change. No significant
relationship was found between the change in _Vo2 at h^L and change in
haemoglobin (r50.27; p50.396).
Figure 1. Showing flow of patients through the study protocol. Post-NACRT tests carried out within
48¡5 hours of finishing NACRT period.
doi:10.1371/journal.pone.0111526.g001
Mitochondrial Function after Cancer Therapy
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Discussion
This is the first study to identify mitochondrial abnormalities accompanying
changes in physical fitness following neoadjuvant chemoradiotherapy. The
benefits of NACRT for locally advanced rectal cancer are improved local disease
control and possibly overall and cancer-specific survival; however its effect on
Table 1. Baseline patient characteristics.
Mean (SD)
Age (years) 69 (10)
Number (%)
Gender Male:Female 10 (83): 2 (17)
Currently smoking 2 (17)
Past medical history
Diabetes 1 (8)
Ischaemic heart disease 2 (17)
Heart failure & cerebrovascular disease 0
American Society of Anaesthesiologists (ASA) score
1 6 (50)
2 6 (50)
World Health Organisation performance status
0 9 (75)
1 3 (25)
Tumour distance from anal verge (cm)
,5.0 cm 6 (50)
5.1–10.0 cm 5 (42)
.10.1 cm 1 (8)
International Union against Cancer Tumour Node Metastasis (TNM) MRI staging
cT3 10 (83)
cT4 2 (17)
cN0 3 (33)
cN1 4 (17)
cN2 5 (50)
cM0 12 (100)
doi:10.1371/journal.pone.0111526.t001
Table 2. Patient characteristics at Baseline and post-NACRT.
Baseline Post-NACRT Mean difference P
mean (SD) mean (SD) (95% CI)
BMI (kg.m22) 26.8 (3.9) 26.3 (3.2) 20.5 (20.5, 1.6) 0.291
FEV1 (l) 3.0 (0.7) 2.9 (0.8) 20.1 (20.1, 0.4) 0.153
FVC (l) 4.3 (0.8) 4.2 (0.9) 20.2 (20.1, 0.4) 0.188
FEV1/FVC (%) 72 (7.3) 73 (7.3) 1.2 (23.1, 0.8) 0.215
Haemoglobin (g.dl21) 13.2 (1.5) 12.9 (1.5) 20.4 (0.5, 0.7) 0.034
doi:10.1371/journal.pone.0111526.t002
Mitochondrial Function after Cancer Therapy
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objectively measured physical fitness has not been measured, nor has the
mechanism of this been explored in vivo.
This pilot study shows a significant reduction in both whole-body physical
fitness measured by CPET ( _Vo2 at h^L 22.36 ml.kg
21.min21, _Vo2 at Peak
23.95 ml.kg21.min21) and in vivo muscle mitochondrial function kPCr
(20.34 min21) between baseline and post-NACRT. We also found a significant
decline in PA with NACRT (21627 steps). This acute decline in mitochondrial
function may account for the rapid loss in fitness and activity over the
neoadjuvant treatment period, clinically important in the context of fitness for
surgery and perioperative risk however causality cannot be established as
controlling for PA in a clinical setting is difficult, and statistical adjustment for PA
in a small patient group is not feasible. These findings however illuminate a
potential mechanistic link that might be contributing to the changes in objectively
Table 3. Patient data at Baseline and post-NACRT.
Baseline Post-NACRT
Mean
difference P
mean (SD) mean (SD) (95% CI)
kPCr
1 (min21) 1.5 (0.5) 1.1 (0.3) 20.4 (20.5,
20.2)
0.001
_Vo2 at h^L (ml.kg
21.min21) 12.3 (3.4) 9.9 (2.2) 22.4 (23.8,
20.9)
0.004
_Vo2 at h^L (L.min
21) 0.9 (0.3) 0.7 (0.2) 20.2 (20.1,
20.3)
0.003
_Vo2 Peak (ml.kg
21.min21) 18.7 (6.1) 14.7 (4.0) 24.0 (26.8,
21.1)
0.011
_Vo2 Peak (L.min
21) 1.4 (0.5) 1.1 (0.3) 20.3 (20.1,
20.5)
0.013
O2 pulse at h^L (ml.beat
21) 8.9 (2.9) 7.7 (2.2) 21.2 (20.2,
22.1)
0.022
O2 pulse at Peak (ml.beat
21) 10.5 (3.6) 8.7 (2.2) 21.8 (20.3,
23.3)
0.024
_VE/ _Vco2 at h^L 34.5 (6.4) 34.2 (4.3) 20.3 (2.5, 23.1) 0.825
_VE/ _Vco2 at Peak 35.9 (4.6) 37.1 (4.8) 0.3 (23.7, 1.4) 0.080
Average number of steps 5352 (3913) 3725 (2217) 21627 (259,
3195)
0.039
median
(IQR)
median
(IQR) (95% CI)
Baseline heart rate (beats.min21) 76 (71, 90) 68 (61, 81) 27 (21.0, 213.9) 0.028
Peak heart rate (beats.min21) 135 (126,
142)
130 (115,
143)
25 (24.1, 14.9) 0.235
Work rate at h^L (W) 55 (39,77) 56 (39,73) 1 (28.4, 9.4) 0.904
Work rate at Peak (W) 109 (71,134) 113 (79,128) 4 (212.2,24.5) 0.475
Abbreviations: kPCr, post-exercise phosphocreatine recovery rate constant; _Vo2 at h^L, oxygen uptake at estimated anaerobic threshold; _Vo2 Peak, oxygen
uptake at peak exercise; O2 pulse at h^L, oxygen pulse at estimated anaerobic threshold; O2 pulse at Peak, oxygen pulse at peak exercise; _VE/ _Vco2 at h^L,
ventilatory equivalents for carbon dioxide at estimated anaerobic threshold; _VE/ _Vco2 at h^L, ventilatory equivalents for carbon dioxide at peak exercise; Work
rate at h^L, work rate at estimated anaerobic threshold; Work rate at Peak, work rate at peak exercise.
doi:10.1371/journal.pone.0111526.t003
Mitochondrial Function after Cancer Therapy
PLOS ONE | DOI:10.1371/journal.pone.0111526 December 5, 2014 9 / 15
measured whole body physical fitness with NACRT, consistent with the results of
our earlier pilot study [21].
Cancer-induced cachexia can cause major loss of skeletal muscle, resulting in
fatigue and higher mortality [31, 32]. In our cohort cancer progression is not a
contributing factor as tumours were downstaged. Furthermore BMI and weight
remained stable. The small but statistically significant fall in haemoglobin is
unlikely to be functionally relevant, and showed no correlation with the CPET or
31P MRS changes.
Figure 2. 31P MRS (kPCr) and CPET ( _Vo2 at h^L and _Vo2 at Peak) data at Baseline (before NACRT)) and at
48¡5 hours post-NACRT: lines link data-points (closed circles) for individual patients, and open
circles show overall mean¡SEM. Mean changes (SEM) between baseline and post-NACRTare for kPCr
20.4(0.1) min21, p50.001; for _Vo2 at h^L 22.4(0.7) ml.kg
21.min21, p50.004; and for _Vo2 Peak 24.0(1.3)
ml.kg21.min21, p50.011.
doi:10.1371/journal.pone.0111526.g002
Figure 3. Averaged number of steps at Baseline (before NACRT)) and at 48¡5 hours post-NACRT:
lines link data-points (closed circles) for individual patients, and open circles show overall
mean¡SEM. Mean change (SEM) between baseline and post-NACRT is 21627(712) steps, p50.039.
doi:10.1371/journal.pone.0111526.g003
Mitochondrial Function after Cancer Therapy
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Several publications postulate mechanisms by which chemotherapy may
contribute to skeletal muscle dysfunction [33]. Oxidative damage [34] resulting
from doxorubicin-based chemotherapy in haematological malignancies causes
sarcopaenia [35], up-regulation of E3 ubiquitin-ligase/MAFbx [35] and
mitochondrial death [36]. Drugs with a quinone moiety can directly interact with
oxygen to generate reactive oxygen species (ROS) causing oxidative stress-
mediated injury to cardiac muscle, kidneys and brain tissue [37], while other
chemotherapeutic agents decrease antioxidant levels [37]; however these
chemotherapy regimens were not used in this cohort. At subcellular levels,
mitochondria are major targets for chemotherapy-induced oxidative stress [36].
Chemotherapy is known to affect cardiorespiratory (causing exercise intolerance)
[38] and microcirculatory function [39], PA [33], but these multifactorial
physiological mechanisms remain elusive.
Mitochondrial function measured by 31P MRS is impaired in a variety of
chronic diseases, as well as primary mitochondrial disease. In peripheral arterial
occlusive disease [30, 40] this mainly reflects impaired O2 delivery to the muscle.
In cardiac failure [41] and COPD [42, 43] it is likely to reflect a multifactorial
pathology including reduced PA, mitochondrial density [44] and ROS mechan-
isms. Similar mechanisms might mediate the decline in physical fitness in our
cohort. The acute decline in PA seen might also contribute to changes in
mitochondrial function and physical fitness. A better understanding and
quantification of the potential mechanisms involved if oxidative injury is present
in this patient cohort is essential to design intervention strategies that will
attenuate the toxicity of chemoradiotherapy agents without compromising their
anticancer effects [36]
Our findings have potential clinical implications because reduced physical
fitness is associated with increased perioperative morbidity and mortality after
major intra-abdominal surgery, especially colorectal surgery [14, 15, 45] Our data
provides the first direct evidence that the benefits of NACRT in tumour
downsizing may be at least partly offset by increased perioperative risk as a result
of reduced physical fitness, related to reduced skeletal muscle mitochondrial
function and activity however causality cannot be established. This proposed
mechanism merits further investigation, as does the possibility of preventive
interventions e.g. by exercise training during the pre-operative period (currently
the focus of our published exercise training study [46]). This is an interventional
pilot study in the same patient cohort scheduled to undergo standardised NACRT
and a 6-week structured, tailored exercise training programme (exercise group
n522) or a control period (n513). Here _Vo2 at h^L significantly reduced between
baseline and post-NACRT (21.9 ml.kg21.min21). In the exercise group _Vo2 at h^L
significantly improved between post-NACRT and week 6 post-NACRT
(+2.1 ml.kg21.min21) whereas control group values were unchanged
(20.7 ml.kg21.min21). Furthermore a randomised controlled study investigating
the potential benefits in physical fitness and quality of life of a 9-week structured
Mitochondrial Function after Cancer Therapy
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responsive endurance training programme following NACRT prior to elective
rectal cancer surgery (PB-PG-0711-25093) is currently recruiting.
This study demonstrates an acute decline in objectively-measured physical
fitness, activity as well as a decline in mitochondrial function using validated and
robust methodology. Particular strengths of our study are the low risk of
confounding by indication [47], the blinded physiological evaluations, the
standardization of the NACRT and the homogenous cancer cohort. Limitations
lie in the observational design, the small sample size of what was designed as a
pilot study and that no adjusting for multiple testing was performed.
In conclusion, NACRT before major rectal cancer surgery significantly reduces
physical fitness objectively assessed by CPET and muscle mitochondrial function
assessed by 31P MRS. The existence of abnormalities at both skeletal-muscle and
whole-body level may perhaps suggest a potential mechanistic relationship in
NACRT which merits further investigation, which could potentially inform
development of tailored interventions in the perioperative period to improve both
physical fitness and mitochondrial function in patients with operable rectal
cancer.
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